Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-23T06:38:48.078Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden

Published online by Cambridge University Press:  08 January 2010

Ingrid Lekander ,
Fredrik Borgström ,
Patrick Svarvar ,
Tryggve Ljung ,
Cheryl Carli  and
Ronald F. van Vollenhoven
Ingrid Lekander
Affiliation:
i3 Innovus and MMC, LIME
Fredrik Borgström
Affiliation:
i3 Innovus and MMC, LIME
Patrick Svarvar
Affiliation:
Schering Plough AB
Tryggve Ljung
Affiliation:
Schering Plough AB
Cheryl Carli
Affiliation:
Karolinska Institute
Ronald F. van Vollenhoven
Affiliation:
Karolinska Institute
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: The objective of this study was to estimate the cost-effectiveness of infliximab use in patients with rheumatoid arthritis (RA) in Swedish clinical practice, based on patient-level data from the Stockholm TNF-alpha follow-up registry (STURE).

Methods: Real-world patient-level data on infliximab use from the STURE registry were implemented in a Markov cohort model, in which health states of functional status were classified according to the Health Assessment Questionnaire Disability Index (HAQ—five categories) and twenty-eight joint count Disease Activity Score (DAS28). The transition probabilities between HAQ and DAS28 states during treatment, as well as discontinuation rates were modeled based on data from the registry for patients using infliximab as their first-line biological treatment. The transition probabilities in the comparator arm, that is, disease progression without biologic treatment, as well as mortality rates, costs, and utilities were based on published literature. The analysis had a societal cost perspective.

Results: Infliximab was associated with an incremental gain in quality-adjusted life-years of 1.02 and an incremental cost of €23,264 per patient compared with progression without biologic treatment, producing an incremental cost-effectiveness ratio (ICER) of €22,830 (SEK211,136 or US$31,230). Sensitivity analyses of input parameters and model assumptions produced ICERs in the range from €18,000 to €47,000.

Conclusions: Results from base-case and sensitivity analyses fell well below established benchmarks for cost-effectiveness in Sweden. The results, therefore, indicated that infliximab treatment for RA has provided good societal value for money in Swedish clinical practice, compared with a scenario of no biological treatment.

Keywords

RAClinical practiceRegistry dataMarkov model
Type
ASSESSMENTS
Information
International Journal of Technology Assessment in Health Care , Volume 26 , Issue 1 , January 2010 , pp. 54 - 61
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Askling, J. Risk for tuberculosis following treatment of rheumatoid arthritis with anti-TNF therapy—the Swedish experience 1998–2008. Ann Rheum Dis. 2009;68 (Suppl 3):422.Google Scholar
2. Askling, J, Fored, CM, Brandt, L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 2005;52:1986–1992.CrossRefGoogle ScholarPubMed
3. Askling, J, Fored, CM, Brandt, L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339–1344.Google Scholar
4. Brennan, A, Bansback, N, Nixon, R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford). 2007;46:1345–1354.CrossRefGoogle ScholarPubMed
5. Brennan, A, Bansback, N, Reynolds, A, Conway, P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford). 2004;43:62–72.CrossRefGoogle ScholarPubMed
6. Chehata, JC, Hassell, AB, Clarke, SA, et al. Mortality in rheumatoid arthritis: Relationship to single and composite measures of disease activity. Rheumatology (Oxford). 2001;40:447–452.CrossRefGoogle ScholarPubMed
7. Chen, YF, Jobanputra, P, Barton, P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess. 2006;10:1–248.CrossRefGoogle Scholar
8. Doan, QV, Chiou, CF, Dubois, RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12:555–569.Google ScholarPubMed
9. Ekman, M, Zethraeus, N, Dahlstrom, U, Hoglund, C. [Cost-effectiveness of bisoprolol in chronic heart failure]. Lakartidningen. 2002;99:646–650.Google ScholarPubMed
10. Geborek, P, Crnkic, M, Petersson, IF, Saxne, T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: Clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis. 2002;61:793–798.Google Scholar
11. Jacobsson, LTH, Lindroth, Y, Marsal, L, Bergström, U, Kobelt, G. Rheumatoid arthritis: What does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden. Scand J Rheumatol. 2007;36:179–183.CrossRefGoogle Scholar
12. Katz, PP. The impact of rheumatoid arthritis on life activities. Arthritis Care Res. 1995;8:272–278.Google Scholar
13. Kobelt, G, Jonsson, L, Young, A, Eberhardt, K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford). 2003;42:326–335.CrossRefGoogle ScholarPubMed
14. Kobelt, G, Lindgren, P, Lindroth, Y, Jacobson, L, Eberhardt, K. Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford). 2005;44:1169–1175.Google Scholar
15. Kobelt, G, Lindgren, P, Singh, A, Klareskog, L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis. 2005;64:1174–1179.CrossRefGoogle ScholarPubMed
16. Kroot, EJ, van Leeuwen, MA, van Rijswijk, MH, et al. No increased mortality in patients with rheumatoid arthritis: Up to 10 years of follow up from disease onset. Ann Rheum Dis. 2000;59:954–958.CrossRefGoogle ScholarPubMed
17. Leden, IRS. Rapport från vårdprocess: Reumatologi dyr läkemedelsbehandling. 2003.Google Scholar
18. LFN Kostnadseffektiva läkemedel—LFN. http://www.tlv.se/upload/Bakgrundsmaterial/kostnadseffektiva-lakemedel.pdf (accessed September 25, 2008)Google Scholar
19. Lindqvist, E, Eberhardt, K. Mortality in rheumatoid arthritis patients with disease onset in the 1980s. Ann Rheum Dis. 1999;58:11–14.Google Scholar
20. Meltzer, D. Accounting for future costs in medical cost-effectiveness analysis. J Health Econ. 1997;16:33–64.CrossRefGoogle ScholarPubMed
21. Pincus, T, Callahan, LF, Sale, WG, et al. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 1984;27:864–872.CrossRefGoogle ScholarPubMed
22. Riise, T, Jacobsen, BK, Gran, JT, Haga, HJ, Arnesen, E. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clin Rheumatol. 2001;20:123–127.Google Scholar
23. Scott, DL, Pugner, K, Kaarela, K, et al. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford). 2000;39:122–132.CrossRefGoogle ScholarPubMed
24. Silman, A, Hochberg, M. Epidemiology of rheumatic diseases. 1993. Oxford: Oxford University Press.CrossRefGoogle Scholar
25. Symmons, DP, Jones, MA, Scott, DL, Prior, P. Longterm mortality outcome in patients with rheumatoid arthritis: Early presenters continue to do well. J Rheumatol. 1998;25:1072–1077.Google Scholar
26. Yelin, E, Trupin, L, Wong, B, Rush, S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol. 2002;29:1851–1857.Google Scholar
27. Young, A, Dixey, J, Kulinskaya, E, et al. Which patients stop working because of rheumatoid arthritis? Results of five years’ follow up in 732 patients from the Early RA Study (ERAS). Ann Rheum Dis. 2002;61:335–340.CrossRefGoogle ScholarPubMed